In a client receiving epoetin alfa for chronic kidney disease, which hematocrit level indicates a therapeutic effect?

In the context of chronic kidney disease, epoetin alfa is a medication used to stimulate erythropoiesis, or red blood cell production, thereby addressing anemia often associated with this condition. A hematocrit level of 33% indicates a therapeutic effect because it falls within the target range for patients undergoing treatment for anemia related to chronic kidney disease.

Therapeutic goals for hematocrit levels in these patients typically range from approximately 33% to 36%. Therefore, a hematocrit level of 33% demonstrates that the epoetin alfa is effectively stimulating the production of red blood cells, helping to alleviate anemia and improve oxygen transport in the body.

Levels below this range, such as 25%, indicate insufficient response to treatment and ongoing anemia. Hematocrit levels significantly higher than 36% can lead to complications such as hypertension and increased risk of cardiovascular events, making those values non-therapeutic and possibly harmful. Thus, the hematocrit level of 33% represents an effective and safe level of response in patients receiving epoetin alfa for anemia management in the context of chronic kidney disease.